493 related articles for article (PubMed ID: 12534347)
21. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
[TBL] [Abstract][Full Text] [Related]
23. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
Behrendt N; Danø K
FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
[TBL] [Abstract][Full Text] [Related]
24. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
25. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
27. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
Egelund R; Petersen TE; Andreasen PA
Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
Ragno P; Montuori N; Rossi G
Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
[TBL] [Abstract][Full Text] [Related]
29. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
[TBL] [Abstract][Full Text] [Related]
30. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
31. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
32. Both pro-uPA and uPA: PAI-1 complex bind to the alpha 2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Gliemann J; Andreasen PA
Ann N Y Acad Sci; 1994 Sep; 737():483-5. PubMed ID: 7944152
[No Abstract] [Full Text] [Related]
33. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.
Higazi AA; Mazar A; Wang J; Reilly R; Henkin J; Kniss D; Cines D
Blood; 1996 May; 87(9):3545-9. PubMed ID: 8611676
[TBL] [Abstract][Full Text] [Related]
34. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
35. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
[TBL] [Abstract][Full Text] [Related]
36. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW
J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090
[TBL] [Abstract][Full Text] [Related]
37. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.
Degryse B; Sier CF; Resnati M; Conese M; Blasi F
FEBS Lett; 2001 Sep; 505(2):249-54. PubMed ID: 11566185
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
39. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
[TBL] [Abstract][Full Text] [Related]
40. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
